Research dossier
Clinical research on Saw Palmetto
10 trials reviewed across 4 indications.
Strongest evidence
BPH and male lower urinary tract symptoms
Mechanism
Saw palmetto's lipidosterolic extract contains fatty acids and phytosterols (notably beta-sitosterol). In vitro it weakly inhibits 5-alpha-reductase (both isoforms) — the enzyme finasteride targets — and shows mild anti-androgen receptor binding and COX/LOX anti-inflammatory effects. Mechanistically plausible. Clinically, the in vivo enzyme inhibition appears far weaker than finasteride: saw palmetto does NOT lower serum PSA in trials (CAMUS confirmed this), while finasteride reliably halves it within 6 months.
The most rigorous evidence is null. STEP (n=225, NEJM 2006) and CAMUS (n=369, JAMA 2011) — including a CAMUS arm at 960 mg/day, triple the standard dose — showed no benefit over placebo on AUA Symptom Index, urinary flow, prostate volume, or PSA. Cochrane 2012 (n=5,666 across 32 trials) confirms. Pierre Fabre-funded Permixon trials (Carraro 1996, Debruyne 2002) report symptom benefit but lack placebo arms.
AUA and EAU guidelines do not recommend saw palmetto as first-line therapy. Men with mild symptoms who specifically want to avoid finasteride's sexual side effects sometimes try the hexane-extracted Permixon formulation — but they should know the placebo-controlled evidence is null. Moderate-to-severe LUTS warrants an alpha-blocker (tamsulosin) or 5-ARI (finasteride/dutasteride).
Trials cited
STEP — Saw Palmetto Treatment for Enlarged Prostates
Null · RCT
Bent et al., 2006, New England Journal of Medicinen=225Double-blind RCT in 225 men with moderate-to-severe BPH. After one year, saw palmetto produced NO statistically significant improvement over placebo on AUA Symptom Index, peak urinary flow, prostate volume, residual urine volume, quality of life, or serum PSA. The single most-cited rigorous saw palmetto trial — and it was negative.
Used a US-sourced ethanol-extracted preparation, which some commentators argued differs from the Permixon hexane extract. CAMUS later tested the standard preparation at escalating doses up to 960 mg/day and replicated the null.
CAMUS — Complementary and Alternative Medicine for Urological Symptoms
Null · RCT
Barry et al., 2011, JAMAn=369NIH-funded double-blind RCT in 369 men. Escalated saw palmetto dosing to 960 mg/day — triple the standard — over 18 months. No difference from placebo on AUA Symptom Index, peak flow, residual volume, prostate size, PSA, or sexual function. Closed the dose-response escape hatch left after STEP. Also confirmed saw palmetto does NOT lower PSA (unlike finasteride).
Used a standardized lipidosterolic extract. The most definitive trial in the field. The fact that 960 mg/day was no better than placebo undercuts the 'we just need a higher dose' argument.
Cochrane review — Serenoa repens for benign prostatic hyperplasia
Null · Systematic review
Tacklind et al., 2012, Cochrane Database of Systematic Reviewsn=5666Cochrane review of 32 RCTs (n=5,666) found saw palmetto, even at double or triple doses, did not improve LUTS or peak flow compared with placebo. The 2009 prior Cochrane review had reached a similarly cautious conclusion. This is the most comprehensive pooled evidence base in the field — and it is null.
Authors noted study heterogeneity in extract type. The 2009 → 2012 updates progressively downgraded the evidence as larger, better-blinded trials accumulated. The trajectory of the literature points one direction.
Earlier Cochrane review — saw palmetto for BPH
Null · Systematic review
Wilt et al., 2009, Cochrane Database of Systematic Reviews (updated)n=3139The 2009 Cochrane update was the first major pooled analysis to downgrade saw palmetto for BPH after STEP entered the dataset. Earlier reviews (Wilt 1998) had been cautiously positive based on smaller, less-rigorous trials. As trial quality improved, the effect size shrank toward zero.
Sets up the trajectory continued by Tacklind 2012. When you replace small open-label trials with large blinded ones, the saw palmetto signal disappears.
PERMAL — Permixon vs finasteride for BPH
mixed · RCT
Carraro et al., 1996, Prostaten=1098Industry-fundedPierre Fabre-funded equivalence trial of 1,098 men comparing Permixon to finasteride. Reported similar IPSS improvements between arms (~37%) and peak-flow gains. No placebo arm — the apparent benefit could be regression to the mean and placebo response, which BPH symptom trials reliably elicit.
Industry-funded by Pierre Fabre (Permixon manufacturer). The lack of a placebo arm is fatal — STEP and CAMUS both showed the placebo arm matches saw palmetto, so an active-comparator trial without placebo cannot distinguish efficacy from placebo response.
PERMAL — Permixon vs tamsulosin for BPH
mixed · RCT
Debruyne et al., 2002, European Urologyn=811Industry-fundedIndustry-funded equivalence trial of Permixon vs the alpha-blocker tamsulosin. Reported similar IPSS reductions (~4–5 points) in both arms over 12 months. No placebo arm, again — the same methodological gap as Carraro 1996.
Pierre Fabre-affiliated. Without a placebo arm and given STEP/CAMUS results, this trial demonstrates only that saw palmetto and tamsulosin produce similar non-specific symptom changes in this study design — not that either beats placebo in this population.
Russo review — Permixon hexane extract clinical data
mixed · Systematic review
Russo et al., 2014, UrologyIndustry-fundedReview (with Pierre Fabre author affiliations) argues that the hexane-extracted lipidosterolic Permixon formulation deserves to be considered separately from generic saw palmetto preparations and that European trials of the specific extract show modest symptom benefit, particularly for nocturia.
Industry-affiliated. The extract-specific argument is real but unresolved — independent replication of Permixon-specific positive results outside Pierre Fabre-funded studies remains thin. The 2012 Cochrane review weighted the totality of evidence as null.
AUA Guideline on Management of BPH
Null · Systematic review
American Urological Association Guideline on BPH (McVary 2011 original, Foster 2018 amended, Lerner 2021 update)AUA guideline does not recommend saw palmetto for BPH symptom management. The panel concluded that saw palmetto has not demonstrated meaningful improvement in LUTS in well-designed trials and recommends alpha-blockers, 5-alpha-reductase inhibitors, or combination therapy as first-line pharmacologic options. EAU guidance is similar.
Position is based on the totality of high-quality evidence including STEP, CAMUS, and the Cochrane reviews. The PERMIXON industry-funded data was reviewed and judged insufficient to overturn the placebo-controlled null findings.
DHT modulation and androgen pathway
Mechanism
In vitro: weak inhibition of both 5-alpha-reductase isoforms; competitive binding at the androgen receptor; phytosterol-mediated anti-inflammatory action. In vivo: the lack of measurable PSA suppression in CAMUS argues the enzymatic effect at clinically realistic doses is too small to alter systemic androgen tone meaningfully.
Saw palmetto is often marketed as a 'natural DHT blocker.' The mechanism is real in cell culture; the clinical reality is that CAMUS specifically demonstrated saw palmetto does NOT lower PSA, which is the most sensitive biomarker of 5-ARI activity. Whatever 5-alpha-reductase inhibition occurs is far weaker than finasteride's.
Because saw palmetto does not lower PSA, men taking it can continue normal PSA-based prostate cancer screening without correction. Finasteride, by contrast, requires doubling the measured PSA to interpret screening results.
STEP — Saw Palmetto Treatment for Enlarged Prostates
Null · RCT
Bent et al., 2006, New England Journal of Medicinen=225Double-blind RCT in 225 men with moderate-to-severe BPH. After one year, saw palmetto produced NO statistically significant improvement over placebo on AUA Symptom Index, peak urinary flow, prostate volume, residual urine volume, quality of life, or serum PSA. The single most-cited rigorous saw palmetto trial — and it was negative.
Used a US-sourced ethanol-extracted preparation, which some commentators argued differs from the Permixon hexane extract. CAMUS later tested the standard preparation at escalating doses up to 960 mg/day and replicated the null.
CAMUS — Complementary and Alternative Medicine for Urological Symptoms
Null · RCT
Barry et al., 2011, JAMAn=369NIH-funded double-blind RCT in 369 men. Escalated saw palmetto dosing to 960 mg/day — triple the standard — over 18 months. No difference from placebo on AUA Symptom Index, peak flow, residual volume, prostate size, PSA, or sexual function. Closed the dose-response escape hatch left after STEP. Also confirmed saw palmetto does NOT lower PSA (unlike finasteride).
Used a standardized lipidosterolic extract. The most definitive trial in the field. The fact that 960 mg/day was no better than placebo undercuts the 'we just need a higher dose' argument.
Androgenetic alopecia (male pattern hair loss)
Mechanism
Downstream extrapolation from the weak 5-alpha-reductase inhibition seen in vitro: if saw palmetto lowered DHT in scalp, it might reduce androgenetic alopecia. The mechanism is the same one underlying finasteride's well-established hair-growth effect — but saw palmetto's enzyme inhibition appears clinically too weak to lower systemic PSA, calling into question whether it lowers scalp DHT meaningfully either.
Evidence is thin. The most-cited trial (Marks 2002) was an n=26 pilot using a multi-ingredient botanical blend. Rossi 2012 (n=100) was open-label with no placebo. No large, rigorous, placebo-controlled RCT of saw palmetto monotherapy for androgenetic alopecia exists. Compared to finasteride (FDA-approved, strong evidence) or minoxidil (FDA-approved), saw palmetto is at best a much weaker fallback.
If finasteride's sexual side effects are a dealbreaker, topical minoxidil is the better-evidenced alternative. Saw palmetto for hair loss is a mechanism-based hope, not a clinically validated treatment.
Marks — saw palmetto for androgenetic alopecia (pilot)
positive · Pilot
Marks et al., 2002, Journal of Alternative and Complementary Medicinen=26Tiny pilot trial (n=26, ~10 in the treatment analysis) reported improved hair growth in 6 of 10 men on the botanical blend versus 1 of 9 on placebo. Almost universally cited as 'evidence' that saw palmetto works for hair loss — but it was a multi-ingredient pilot, not a saw-palmetto-only trial, and the sample is too small for any confident conclusion.
n=26 pilot, multi-ingredient formulation, soft investigator-rated endpoint. No rigorous large RCT of saw palmetto monotherapy for androgenetic alopecia has ever been conducted. The hair-loss claim outruns the data.
Rossi — saw palmetto vs finasteride for androgenetic alopecia (open-label)
mixed · RCT
Rossi et al., 2012, International Journal of Immunopathology and Pharmacologyn=100Open-label comparison of saw palmetto to finasteride in 100 men with androgenetic alopecia. Both arms showed improvement in investigator ratings, with finasteride producing larger and more consistent gains. The trial is widely cited as showing saw palmetto 'works,' but it was unblinded with no placebo arm.
Open-label, no placebo, subjective endpoint. In hair-loss trials, unblinded designs reliably produce inflated positive results because both clinicians and patients want the intervention to work. Cannot establish efficacy.
Prostate health maintenance
Mechanism
Anti-inflammatory phytosterols and fatty acids may modestly affect prostate inflammation in animal and in vitro work. The 'general prostate support' positioning rests on this mechanistic story rather than on hard clinical endpoints in healthy men.
There is no RCT showing that saw palmetto in men without BPH prevents BPH, prostate cancer, or any other prostate outcome. The 'preventive prostate support' marketing claim is mechanistic extrapolation, not evidence-based.
Healthy men with no urinary symptoms have no documented evidence-based reason to take saw palmetto. Save the money for diet, weight management, and regular checkups.
Cochrane review — Serenoa repens for benign prostatic hyperplasia
Null · Systematic review
Tacklind et al., 2012, Cochrane Database of Systematic Reviewsn=5666Cochrane review of 32 RCTs (n=5,666) found saw palmetto, even at double or triple doses, did not improve LUTS or peak flow compared with placebo. The 2009 prior Cochrane review had reached a similarly cautious conclusion. This is the most comprehensive pooled evidence base in the field — and it is null.
Authors noted study heterogeneity in extract type. The 2009 → 2012 updates progressively downgraded the evidence as larger, better-blinded trials accumulated. The trajectory of the literature points one direction.
Russo review — Permixon hexane extract clinical data
mixed · Systematic review
Russo et al., 2014, UrologyIndustry-fundedReview (with Pierre Fabre author affiliations) argues that the hexane-extracted lipidosterolic Permixon formulation deserves to be considered separately from generic saw palmetto preparations and that European trials of the specific extract show modest symptom benefit, particularly for nocturia.
Industry-affiliated. The extract-specific argument is real but unresolved — independent replication of Permixon-specific positive results outside Pierre Fabre-funded studies remains thin. The 2012 Cochrane review weighted the totality of evidence as null.
1 forms of Saw Palmetto compared
CO2 supercritical-extracted saw palmetto
Standardized fatty acid + sterol concentration; better solvent residue profile than older extraction methods
Best forBPH symptom support at the 320 mg/day standard dose if you specifically want to try saw palmettoSupercritical CO2 extraction preserves the lipid/sterol profile without ethanol or hexane residues. The placebo-controlled BPH evidence is still null at this preparation; extract method does not appear to rescue the clinical signal.
Are you deficient? Symptoms, risk groups, lab tests
Saw palmetto is not an essential nutrient. There is no deficiency syndrome and no RDA. It is a phytotherapy — a plant extract used as a botanical intervention, not a nutrient being replaced.
Common symptoms
- Not applicable — saw palmetto is not a deficiency-driven supplement
- Listed only for cross-reference: the conditions men commonly try saw palmetto for are urinary frequency, weak stream, nocturia, incomplete bladder emptying (BPH symptoms), and male-pattern hair thinning
Who is at risk
Men with mild-to-moderate BPH symptoms (AUA Symptom Index 8–18)
Common reason men reach for saw palmetto. The honest take: STEP and CAMUS specifically enrolled this population and found no benefit over placebo. An alpha-blocker (e.g., tamsulosin) provides faster, evidence-backed symptom relief in days to weeks.
Men avoiding finasteride or dutasteride due to sexual side effects
5-ARI medications can cause decreased libido, erectile dysfunction, and ejaculatory changes in 3–8% of users; post-finasteride syndrome is a separate ongoing controversy. Some men try saw palmetto as a milder alternative. The trade-off is that saw palmetto's BPH effect in placebo-controlled trials is also null — you may be trading side-effect risk for no benefit at all.
Men with early androgenetic alopecia avoiding finasteride
Same reasoning as above for hair loss. Topical minoxidil is the better-evidenced non-finasteride option. Oral saw palmetto for hair loss has only a tiny n=26 pilot and an open-label n=100 trial supporting it.
Men with mild nocturia bothered by sleep disruption
Permixon-funded reviews suggest a modest nocturia signal in their extract specifically, though placebo-controlled confirmation outside Pierre Fabre-funded research is thin. Behavioral measures (fluid timing, evening alcohol limits, screening for sleep apnea) are higher-yield first steps.
Lab markers
Serum PSA (prostate-specific antigen)
Important: saw palmetto does NOT suppress PSA (CAMUS confirmed this). Routine PSA screening interpretation is unaffected. This is unlike finasteride or dutasteride, where PSA must be doubled to interpret screening accurately.
- Typical reference for men under 50
- <2.5 ng/mL
- Typical reference for men 50–59
- <3.5 ng/mL
- Typical reference for men 60–69
- <4.5 ng/mL
Side effects and drug interactions
Side effects
Mild GI upset (nausea, stomach pain, diarrhea, constipation)
Common
The most commonly reported side effect across the BPH trials. Generally mild, usually resolves with food or dose timing. STEP and CAMUS both reported saw palmetto and placebo arms with similar low rates of GI complaints.
Headache
Uncommon
Mild and usually transient. Reported at similar low rates to placebo in the major trials.
Decreased libido or erectile changes
Uncommon
Reported at low rates in saw palmetto BPH trials, generally not statistically different from placebo. This is in contrast to finasteride and dutasteride, where sexual side effects are well-documented and dose-related.
Gynecomastia or breast tenderness in men
Rare
Rare case reports; mechanism would relate to weak anti-androgen activity. Not consistently reproduced in controlled trials.
Bleeding events with anticoagulants or antiplatelets
Rare
Saw palmetto may have mild antiplatelet effects. Case reports describe bleeding events when stacked with warfarin or aspirin. Consider stopping 2 weeks before elective surgery.
Liver enzyme elevation / cholestatic hepatitis
Rare
Isolated case reports of acute liver injury attributed to saw palmetto. Causality is often uncertain because multi-ingredient herbal blends are commonly involved. Discontinue if jaundice, dark urine, or unexplained fatigue occurs.
Pancreatitis
Rare
Very rare case reports. Mechanism unclear; not seen in controlled trials.
Drug interactions
Additive effect
warfarinaspirinclopidogrelrivaroxabanapixabandabigatranNSAIDsSaw palmetto has reported mild antiplatelet activity. Case reports describe excess bleeding and elevated INR when combined with anticoagulants or chronic NSAID use.
Avoid stacking with anticoagulants without prescriber oversight. Discontinue saw palmetto 2 weeks before elective surgery or dental extractions.
Other
finasteridedutasteridespironolactonebicalutamideflutamideTheoretical additive anti-androgen activity. In practice, saw palmetto's clinical androgen effect is so weak (it does not lower PSA) that meaningful stacking interactions are unlikely — but the combination is rarely useful given saw palmetto's null evidence.
Adding saw palmetto to an evidence-based 5-ARI provides no demonstrated additional benefit. Pick one strategy.
Other
oral contraceptiveshormone replacement therapytamoxifenTheoretical hormonal interactions in women. Saw palmetto is not indicated in women, and any anti-androgen activity could interfere with hormone therapies.
Avoid saw palmetto in women on hormone therapies. Specifically contraindicated in pregnancy, breastfeeding, and hormone-sensitive conditions.
Other
alpha-blockers (tamsulosin, alfuzosin, doxazosin)Concurrent use is sometimes done in clinical practice but provides no documented additive benefit. Alpha-blockers are evidence-based first-line; saw palmetto is not.
No clear interaction risk, but no clear benefit either. If symptoms are bothersome enough to need a real alpha-blocker, the saw palmetto isn't doing meaningful work.
Other critical caveats
- STEP (NEJM 2006, n=225) and CAMUS (JAMA 2011, n=369) — the two most rigorous saw palmetto trials ever conducted — both found no benefit over placebo for BPH symptoms, urinary flow, prostate size, or PSA. CAMUS specifically escalated to 960 mg/day, triple the standard dose, and remained null. The 2012 Cochrane review of 32 trials (n=5,666) replicated the null. The popular use of saw palmetto for BPH dramatically exceeds the placebo-controlled evidence.
- The American Urological Association does not recommend saw palmetto as a treatment for BPH. Standard pharmacologic care for bothersome LUTS is an alpha-blocker (tamsulosin), a 5-alpha-reductase inhibitor (finasteride or dutasteride), or combination therapy — all with substantially stronger evidence than saw palmetto.
- Avoid saw palmetto in pregnancy, breastfeeding, and women with hormone-sensitive conditions. The weak anti-androgen activity creates a theoretical risk to fetal development and to women on hormone therapies. Saw palmetto is a male-pattern phytotherapy; routine female use is not supported.
- Saw palmetto does NOT suppress PSA (CAMUS confirmed this directly). This is actually clinically useful: men on saw palmetto can interpret routine PSA screening normally, unlike men on finasteride/dutasteride who must double the measured value. Saw palmetto does NOT mask prostate cancer screening.
- Stop saw palmetto at least 2 weeks before elective surgery or dental extraction due to reported mild antiplatelet activity and rare bleeding case reports, especially when stacked with warfarin, NSAIDs, or aspirin.
- The Pierre Fabre-funded Permixon trials (Carraro 1996, Debruyne 2002, Russo 2014 review) report positive results for the hexane-extracted lipidosterolic preparation, but most lack placebo arms. STEP and CAMUS show that placebo arms in BPH trials match saw palmetto, so active-comparator-only designs cannot demonstrate efficacy. Independent replication of Permixon-specific positive results remains limited.
- The hair-loss claim rests on a single n=26 pilot (Marks 2002, multi-ingredient blend) and an n=100 open-label trial (Rossi 2012, no placebo). For androgenetic alopecia, finasteride and topical minoxidil are the evidence-based options. Saw palmetto for hair is a mechanistic hope, not a clinically validated treatment.
Frequently asked
Does saw palmetto actually work for BPH?
The honest answer: the most rigorous trials say no. STEP (NEJM 2006, n=225) and CAMUS (JAMA 2011, n=369) — including CAMUS at 960 mg/day, triple the standard dose — found no benefit over placebo on AUA Symptom Index, urinary flow, prostate volume, or PSA. The 2012 Cochrane review of 32 trials (n=5,666) reached the same conclusion. The AUA does not recommend it as first-line therapy. Permixon-funded European trials report positive results but lack placebo arms, which makes them uninterpretable given the strong placebo response BPH trials reliably show.What about hair loss? I see saw palmetto in every 'natural DHT blocker' product.
The hair-loss evidence is much weaker than the marketing implies. The most-cited trial (Marks 2002) was an n=26 pilot using a multi-ingredient botanical blend, not saw palmetto alone. Rossi 2012 (n=100) was open-label with no placebo. No rigorous large RCT of saw palmetto monotherapy for androgenetic alopecia exists. The mechanistic story (5-alpha-reductase inhibition like finasteride) is appealing, but saw palmetto's in vivo enzymatic activity is too weak to even lower PSA. For real androgenetic alopecia, finasteride and topical minoxidil are the evidence-based options.Is the hexane Permixon extract different from cheap saw palmetto?
Pierre Fabre's hexane-extracted lipidosterolic Permixon is the most-studied branded extract globally and has more positive trials than generic preparations — but those trials are almost entirely manufacturer-funded and most lack placebo arms. The 2012 Cochrane review pooled all extract types and was still null overall. The extract-quality argument is real; the case that it rescues the clinical signal is not yet proven outside Pierre Fabre-affiliated research. Cheap whole-berry powder products without standardization are even less defensible.Saw palmetto vs finasteride or tamsulosin — which should I take?
For bothersome BPH symptoms, the evidence-based pharmacologic options are alpha-blockers (tamsulosin, alfuzosin) for rapid symptom relief (days to weeks) or 5-alpha-reductase inhibitors (finasteride, dutasteride) for prostate-shrinking effect over months. Both have far stronger evidence than saw palmetto. The reason some men try saw palmetto is to avoid finasteride's sexual side effects (3–8% of users) — but in placebo-controlled trials, saw palmetto produced no benefit either. You may be trading documented side-effect risk for null efficacy. Discuss options with a urologist if symptoms are bothersome.Can women take saw palmetto?
No, not in pregnancy or breastfeeding, and routinely avoid in women with hormone-sensitive conditions. Saw palmetto has weak anti-androgen activity, creating theoretical risk to fetal development and to women on hormone therapies. It is a phytotherapy historically used for male urinary symptoms; there is no evidence base for routine female use, and the safety signal is unfavorable.Will saw palmetto affect my PSA test?
No — and this is actually clinically useful. CAMUS specifically demonstrated saw palmetto does NOT suppress PSA. Routine PSA-based prostate cancer screening can be interpreted normally on saw palmetto. This is in contrast to finasteride and dutasteride, where measured PSA must be doubled to interpret screening accurately. Saw palmetto does not mask prostate cancer.Is saw palmetto safe?
Generally well-tolerated. Most common side effects are mild GI upset, headache, and (rarely) decreased libido — usually at rates similar to placebo. Important cautions: mild antiplatelet activity means stop saw palmetto 2 weeks before elective surgery, and avoid stacking with warfarin, aspirin, or chronic NSAIDs without prescriber oversight. Rare case reports describe acute liver injury — discontinue if jaundice or dark urine occurs. Avoid in pregnancy, breastfeeding, and women on hormone therapies.
References
- 01Bent et al., 2006, NEJM — Saw Palmetto for Benign Prostatic Hyperplasia (STEP trial)
- 02Barry et al., 2011, JAMA — CAMUS Trial: Effect of Increasing Doses of Saw Palmetto on LUTS
- 03Tacklind et al., 2012, Cochrane Database — Serenoa repens for benign prostatic hyperplasia
- 04AUA Guideline — Management of Lower Urinary Tract Symptoms Attributed to BPH (2021 update)
- 05NCCIH — Saw Palmetto (NIH National Center for Complementary and Integrative Health)
- 06NIH Office of Dietary Supplements — Botanical Dietary Supplements Background Information
- 07EAU Guideline — Management of Non-Neurogenic Male LUTS (European Association of Urology)
Last reviewed2026-05-22